A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

NCT01878617 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

660

Enrollment

OTHER

Sponsor class

Conditions

Medulloblastoma

Interventions

RADIATION: Craniospinal Irradiation with boost to the primary tumor site
DRUG: Cyclophosphamide
DRUG: Cisplatin
DRUG: Vincristine
DRUG: Vismodegib
DRUG: Pemetrexed
DRUG: Gemcitabine
OTHER: Aerobic Training
OTHER: Neurocognitive Remediation

Sponsor

St. Jude Children's Research Hospital

Collaborators

[object Object]
[object Object]